Novel therapeutic strategies for osteoarthritis: from mechanistic insights to precision medicine

Abstract

Osteoarthritis (OA) is a prevalent chronic degenerative joint disease that significantly impacts the quality of life for over 500 million individuals affected. OA is increasingly recognized as a whole-joint disorder characterized by complex biochemical and cellular changes across various joint tissues. However, traditional approaches such as nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids often fall short in halting disease progression or restoring joint function. Thereby, recent innovations in OA management are focused on underlying pathophysiology, driving the development of regenerative therapies, targeted anti-inflammatory agents and senolytic or senomorphic approaches. Accordingly, this paper reviews current progress in these areas by integrating evidence from clinical and pre-clinical studies to clarify therapeutic limitations, unresolved mechanistic and phenotypic gaps and the emerging strategies required to advance disease-modifying therapy in OA. It further outlines pathways toward precision, phenotype-aligned interventions, an integration that current literature has not yet consolidated.

References

[1] Huang X, Wang Z, Wang H, Chen D, Tong L. Novel strategies for the treatment of osteoarthritis based on biomaterials and critical molecular signaling. J. Mater. Sci. Technol., 2023, 149: 42-55.

[2] Cai X, et al.. New trends in pharmacological treatments for osteoarthritis. Front. Pharmacol., 2021, 12. ArticleID: 645842

[3] Grässel, S. & Muschter, D. Recent advances in the treatment of osteoarthritis. F1000Research9, F1000 (2020).

[4] Lv Z, Wang Z, Chen D, Shi D. Advances in osteoarthritis research: from diagnosis, treatment to mechanism studies. J. Orthop. Transl., 2024, 44: A4

[5] Chen, L., Zhang, Z. & Liu, X. Role and mechanism of mechanical load in the homeostasis of the subchondral bone in knee osteoarthritis: a comprehensive review. J. Inflamm. Res.17, 9359–9378 (2024).

[6] Yan Y, et al.. Axin2 controls bone remodeling through the β-catenin–BMP signaling pathway in adult mice. J. Cell Sci., 2009, 122: 3566-3578.

[7] Lories RJ, Monteagudo S. Review article: Is Wnt signaling an attractive target for the treatment of osteoarthritis?. Rheumatol. Ther., 2020, 7: 259-270.

[8] Shen J, Li S, Chen D. TGF-β signaling and the development of osteoarthritis. Bone Res., 2014, 2: 1-7.

[9] Lu K, et al.. Molecular signaling in temporomandibular joint osteoarthritis. J. Orthop. Transl., 2022, 32: 21-27

[10] Kulm S, et al.. Genetic risk factors for end-stage hip osteoarthritis treated with total hip arthroplasty: a genome-wide association study. J. Arthroplast., 2023, 38: 2149-2153.e2141.

[11] Kenny J, et al.. Age-dependent genetic regulation of osteoarthritis: independent effects of immune system genes. Arthritis Res Ther., 2023, 25: 232.

[12] Richard D, Capellini TD, Diekman BO. Epigenetics as a mediator of genetic risk in osteoarthritis: role during development, homeostasis, aging, and disease progression. Am. J. Physiol. Cell Physiol., 2023, 324: C1078-c1088.

[13] Dell’Isola A, Allan R, Smith SL, Marreiros SSP, Steultjens M. Identification of clinical phenotypes in knee osteoarthritis: a systematic review of the literature. BMC Musculoskelet. Disord., 2016, 17. ArticleID: 425

[14] Roemer FW, et al.. Structural phenotypes of knee osteoarthritis: potential clinical and research relevance. Skelet. Radiol., 2023, 52: 2021-2030.

[15] Magni A, et al.. Management of osteoarthritis: expert opinion on NSAIDs. Pain. Ther., 2021, 10: 783-808.

[16] Tong L, Wijnen AJV, Wang H, Chen D. Advancing bone biology: the mutual promotion of biology and pioneering technologies. Innov. Life, 2024, 2: 100078.

[17] Khan, A., Calinas Correia, J. & Walsh, D. A. Arthritis pain; rheumatoid arthritis, osteoarthritis, and fibromyalgia. in Chronic Pain Management in General and Hospital Practice (eds Shimoji, K., Nader, A., Hamann, W.) 483–515 (Springer, 2021).

[18] Dagnino APA, Campos MM. Chronic pain in the elderly: mechanisms and perspectives. Front. Human Neurosci., 2022, 16: 736688.

[19] Marks R. Knee joint neural pathways and their osteoarthritis pathogenic linkage implications. Acta Sci. Orthop., 2022, 5: 116-126.

[20] Sanchez-Lopez E, Coras R, Torres A, Lane NE, Guma M. Synovial inflammation in osteoarthritis progression. Nat. Rev. Rheumatol., 2022, 18: 258-275.

[21] D’Arcy Y, et al.. Treating osteoarthritis pain: mechanisms of action of acetaminophen, nonsteroidal anti-inflammatory drugs, opioids, and nerve growth factor antibodies. Postgrad. Med., 2021, 133: 879-894.

[22] Puntillo, F. et al. Pathophysiology of musculoskeletal pain: a narrative review. Ther. Adv. Musculoskelet. Dis.13 (2021).

[23] Wood MJ, Miller RE, Malfait A-M. The genesis of pain in osteoarthritis: inflammation as a mediator of osteoarthritis pain. Clin. Geriatr. Med., 2022, 38: 221-238.

[24] De Roover A, Escribano-Núñez A, Monteagudo S, Lories R. Fundamentals of osteoarthritis: inflammatory mediators in osteoarthritis. Osteoarthr. Cartil., 2023, 31: 1303-1311.

[25] Marchand, S. in The Pain Phenomenon 59–104 (Springer, 2024).

[26] Ohashi, Y., Uchida, K., Fukushima, K., Inoue, G. & Takaso, M. Mechanisms of peripheral and central sensitization in osteoarthritis pain. Cureus15, e35331 (2023).

[27] Wyns A, et al.. The biology of stress intolerance in patients with chronic pain—state of the art and future directions. J. Clin. Med., 2023, 12: 2245.

[28] Hu W, Chen Y, Dou C, Dong S. Microenvironment in subchondral bone: predominant regulator for the treatment of osteoarthritis. Ann. Rheum. Dis., 2021, 80: 413-422.

[29] O’Neill TW, Felson DT. Mechanisms of Osteoarthritis (OA) pain. Curr. Osteoporos. Rep., 2018, 16: 611-616.

[30] Neogi T, et al.. Association between radiographic features of knee osteoarthritis and pain: results from two cohort studies. BMJ, 2009, 339: b2844.

[31] Perrot S, Anne-Priscille T. Pain in osteoarthritis from a symptom to a disease. Best. Pract. Res. Clin. Rheumatol., 2023, 37: 101825.

[32] Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet, 2019, 393: 1745-1759.

[33] Cross M, et al.. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann. Rheum. Dis., 2014, 73: 1323-1330.

[34] Yao Q, et al.. Osteoarthritis: pathogenic signaling pathways and therapeutic targets. Signal Transduct. Target Ther., 2023, 8: 56.

[35] Raud B, et al.. Level of obesity is directly associated with the clinical and functional consequences of knee osteoarthritis. Sci. Rep., 2020, 10. ArticleID: 3601

[36] Loeser RF, Collins JA, Diekman BO. Ageing and the pathogenesis of osteoarthritis. Nat. Rev. Rheumatol., 2016, 12: 412-420.

[37] Eymard F, et al.. MRI and ultrasonography for detection of early interphalangeal osteoarthritis. Jt. Bone Spine, 2022, 89. ArticleID: 105370

[38] Tuerxun P, Ng T, Zhao K, Zhu P. Integration of metabolomics and transcriptomics provides insights into the molecular mechanism of temporomandibular joint osteoarthritis. PLoS ONE, 2024, 19: e0301341.

[39] Lopez AN, Bazer FW, Wu G. Functions and metabolism of amino acids in bones and joints of cats and dogs. Adv. Exp. Med. Biol., 2024, 1446: 155-175.

[40] Steinmeyer J. Phospholipids and sphingolipids in osteoarthritis. Biomolecules, 2025, 15: 250.

[41] Li K, et al.. Anti-inflammatory and pro-anabolic effects of 5-aminosalicylic acid on human inflammatory osteoarthritis models. J. Orthop. Transl., 2023, 38: 106-116

[42] Chen T, et al.. Update on novel non-operative treatment for osteoarthritis: current status and future trends. Front. Pharmacol., 2021, 12: 755230.

[43] Preece SJ, et al.. A new integrated behavioural intervention for knee osteoarthritis: development and pilot study. BMC Musculoskelet. Disord., 2021, 22. ArticleID: 526

[44] Woś I, Tabarkiewicz J. Effect of interleukin-6,-17,-21,-22, and-23 and STAT3 on signal transduction pathways and their inhibition in autoimmune arthritis. Immunol. Res., 2021, 69: 26-42.

[45] Zakiyah W, et al.. Literature review: study of molecular mechanism level of NSAID class of drugs as COX-2 inhibitors. J. EduHealth, 2022, 13: 572-580

[46] de Morais SV, et al.. Impact of cuminaldehyde and indomethacin co-administration on inflammatory responses in MIA-induced osteoarthritis in rats. Pharmaceuticals, 2024, 17: 630.

[47] Arabia, M., Maretti, E., Sedighidarijani, A., Rustichelli, C. & Leo, E. Optimizing formulation conditions of PLGA microparticles to enhance indomethacin encapsulation. Part. Part. Syst. Charact. 42, 2400135 (2024).

[48] Xiang H, et al.. MMP13-responsive hydrogel microspheres for osteoarthritis treatment by precise delivery of celecoxib. Mater. Des., 2024, 241. ArticleID: 112966

[49] Roda A, et al.. The effect of a two-in-one viscosupplement delivering celecoxib in a rat model of osteoarthritis. Osteoarthr. Cartil., 2024, 32: S294.

[50] Roda A, Paiva A, Rita C. Duarte A. A low transition temperature mixture-based viscosupplementation complemented with celecoxib for osteoarthritis treatment. Int. J. Pharm., 2024, 656. ArticleID: 124088

[51] Khandelia R, et al.. Reproducible synthesis of biocompatible albumin nanoparticles designed for intra-articular administration of celecoxib to treat osteoarthritis. ACS Appl. Mater. Interfaces, 2024, 16: 14633-14644.

[52] Wang Y, et al.. Efficacy and safety of Gutong Patch compared with NSAIDs for knee osteoarthritis: a real-world multicenter, prospective cohort study in China. Pharmacol. Res., 2023, 197. ArticleID: 106954

[53] Galozzi P, Bindoli S, Doria A, Sfriso P. The revisited role of interleukin-1 alpha and beta in autoimmune and inflammatory disorders and in comorbidities. Autoimmun. Rev., 2021, 20: 102785.

[54] He M, et al.. FSGT capsule inhibits IL-1β-induced inflammation in chondrocytes and ameliorates osteoarthritis by upregulating LncRNA PACER and downregulating COX2/PGE2. Immun., Inflamm. Dis., 2024, 12. ArticleID: e1334

[55] Franco-Trepat E, et al.. Amitriptyline blocks innate immune responses mediated by toll-like receptor 4 and IL-1 receptor: preclinical and clinical evidence in osteoarthritis and gout. Br. J. Pharmacol., 2022, 179: 270-286.

[56] Su C-H, et al.. Betulin suppresses TNF-α and IL-1β production in osteoarthritis synovial fibroblasts by inhibiting the MEK/ERK/NF-κB pathway. J. Funct. Foods, 2021, 86. ArticleID: 104729

[57] Zhan J, et al.. Lycopene inhibits IL-1β-induced inflammation in mouse chondrocytes and mediates murine osteoarthritis. J. Cell. Mol. Med., 2021, 25: 3573-3584.

[58] Murata K, et al.. Effects of IL-6, JAK, TNF inhibitors, and CTLA4-Ig on knee symptoms in patients with rheumatoid arthritis. Sci. Rep., 2024, 14. ArticleID: 15226

[59] Mima Z, et al.. Blockade of JAK2 retards cartilage degeneration and IL-6-induced pain amplification in osteoarthritis. Int. Immunopharmacol., 2022, 113. ArticleID: 109340

[60] Teng H, et al.. Dexamethasone liposomes alleviate osteoarthritis in miR-204/-211-deficient mice by repolarizing synovial macrophages to M2 phenotypes. Mol. Pharm., 2023, 20: 3843-3853.

[61] Chen N, et al.. Single dose thermoresponsive dexamethasone prodrug completely mitigates joint pain for 15 weeks in a murine model of osteoarthritis. Nanomed. Nanotechnol. Biol. Med., 2024, 57. ArticleID: 102735

[62] Gandhi Y, et al.. Advances in anti-inflammatory medicinal plants and phytochemicals in the management of arthritis: a comprehensive review. Food Chem. Adv., 2022, 1. ArticleID: 100085

[63] Prasad P, et al.. Rheumatoid arthritis: advances in treatment strategies. Mol. Cell. Biochem., 2023, 478: 69-88.

[64] Wang Y, et al.. Methotrexate to treat hand osteoarthritis with synovitis (METHODS): an Australian, multisite, parallel-group, double-blind, randomised, placebo-controlled trial. Lancet, 2023, 402: 1764-1772.

[65] Kingsbury SR, et al.. Pain reduction with oral methotrexate in knee osteoarthritis: a randomized, placebo-controlled clinical trial. Ann. Intern Med., 2024, 177: 1145-1156.

[66] Richard SA, et al.. Elucidating the pivotal immunomodulatory and anti-inflammatory potentials of chloroquine and Hydroxychloroquine. J. Immunol. Res., 2020, 2020. ArticleID: 4582612

[67] Kedor C, et al.. Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study—a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. RMD open, 2021, 7. ArticleID: e001660

[68] Zhao C, et al.. Sulfasalazine promotes ferroptosis through AKT-ERK1/2 and P53-SLC7A11 in rheumatoid arthritis. Inflammopharmacology, 2024, 32: 1277-1294.

[69] Jang D-i, et al.. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics. Int. J. Mol. Sci., 2021, 22: 2719.

[70] Poutoglidou F, et al.. Infliximab prevents systemic bone loss and suppresses tendon inflammation in a collagen-induced arthritis rat model. Inflammopharmacology, 2021, 29: 661-672.

[71] Chen, W. et al. Intraarticular injection of infliximab-loaded thermosensitive hydrogel alleviates pain and protects cartilage in rheumatoid arthritis. J. Pain Res. 13, 3315–3329 (2020).

[72] Wen, Z.-H. et al. Effects of etanercept on experimental osteoarthritis in rats: role of histone deacetylases. Cartilage10, 19476035241264012 (2024).

[73] Abbafati, C. et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet396, 1204–1222 (2020).

[74] Maqbool M, et al.. An up to date on clinical prospects and management of osteoarthritis. Ann. Med. Surg., 2021, 72. ArticleID: 103077

[75] Yunus MHM, Nordin A, Kamal H. Pathophysiological perspective of osteoarthritis. Medicina, 2020, 56: 614.

[76] McIlwraith, C. W., Kawcak, C., Baxter, G. M., Goodrich, L. R. & Valberg, S. J. Principles of musculoskeletal disease: joint injuries and disease and osteoarthritis. in Adams and Stashak’s Lameness in Horses (ed Baxter, G. M.). 801–874 (Wiely, 2020).

[77] Fan X, Wu X, Crawford R, Xiao Y, Prasadam I. Macro, micro, and molecular. Changes of the osteochondral interface in osteoarthritis development. Front. Cell Dev. Biol., 2021, 9: 659654.

[78] Zhou J-Q, Wan H-Y, Wang Z-X, Jiang N. Stimulating factors for regulation of osteogenic and chondrogenic differentiation of mesenchymal stem cells. World J. Stem Cells, 2023, 15: 369.

[79] Shu DY, Lovicu FJ. Insights into bone morphogenetic protein - (BMP-) signaling in ocular lens biology and pathology. Cells, 2021, 10: 2604.

[80] Loh H-Y, et al.. Post-transcriptional regulatory crosstalk between MicroRNAs and canonical TGF-β/BMP signalling cascades on osteoblast lineage: a comprehensive review. Int. J. Mol. Sci., 2023, 24: 6423.

[81] Zhang C, Lin Y, Yan CH, Zhang W. Adipokine signaling pathways in osteoarthritis. Front. Bioeng. Biotechnol., 2022, 10: 865370.

[82] Sangadala S, et al.. Sclerostin small-molecule inhibitors promote osteogenesis by activating canonical Wnt and BMP pathways. eLife, 2023, 12. ArticleID: e63402

[83] Bordukalo-Nikšić T, Kufner V, Vukičević S. The role of BMPs in the regulation of osteoclasts resorption and bone remodeling: from experimental models to clinical applications. Front. Immunol., 2022, 13: 869422.

[84] Zhao HJ, et al.. Bone morphogenetic protein 2 promotes human trophoblast cell invasion and endothelial-like tube formation through ID1-mediated upregulation of IGF binding protein-3. FASEB J., 2020, 34: 3151-3164.

[85] Li H, et al.. Simvastatin retards cartilage degradation and subchondral bone deterioration induced by a high-fat diet in mice. CyTA J. Food, 2023, 21: 561-569.

[86] Bei M, et al.. Effects of alendronate on cartilage lesions and micro-architecture deterioration of subchondral bone in patellofemoral osteoarthritic ovariectomized rats with patella-baja. J. Orthop. Surg. Res., 2024, 19. ArticleID: 197

[87] Guo Y, et al.. Imrecoxib and celecoxib affect sacroiliac joint inflammation in axSpA by regulating bone metabolism and angiogenesis. Clin. Rheumatol., 2023, 42: 1585-1592.

[88] Zou M-L, et al.. The Smad dependent TGF-β and BMP signaling pathway in bone remodeling and therapies. Front. Mol. Biosci., 2021, 8. ArticleID: 593310

[89] Zhu X, et al.. Inhibition of TGF-β2–induced trabecular meshwork fibrosis by pirfenidone. Transl. Vis. Sci. Technol., 2023, 12: 21-21.

[90] Zhu X, et al.. Intra-articular sustained-release of pirfenidone as a disease-modifying treatment for early osteoarthritis. Bioact. Mater., 2024, 39: 255-272

[91] Wei Q, et al.. Pirfenidone attenuates synovial fibrosis and postpones the progression of osteoarthritis by anti-fibrotic and anti-inflammatory properties in vivo and in vitro. J. Transl. Med., 2021, 19: 1-12

[92] Lee AJ, et al.. Sustained delivery of SB-431542, a type I transforming growth factor beta-1 receptor inhibitor, to prevent arthrofibrosis. Tissue Eng. Part A, 2021, 27: 1411-1421.

[93] Thielen NGM, et al.. Separating friend from foe: inhibition of TGF-β-induced detrimental SMAD1/5/9 phosphorylation while maintaining protective SMAD2/3 signaling in OA chondrocytes. Osteoarthr. Cartil., 2023, 31: 1481-1490.

[94] Wang X, Yamauchi K, Mitsunaga T. A review on osteoclast diseases and osteoclastogenesis inhibitors recently developed from natural resources. Fitoterapia, 2020, 142: 104482.

[95] Gielis WP, et al.. First clinical results of the zodiak trial: a randomized controlled trial comparing the therapeutic effect of zoledronic acid vs placebo in knee osteoarthritis. Osteoarthr. Cartil., 2024, 32: S593-S594.

[96] De Leon-Oliva D, et al.. The RANK–RANKL–OPG system: a multifaceted regulator of homeostasis, immunity, and cancer. Medicina, 2023, 59: 1752.

[97] Liang J, et al.. Therapeutics of osteoarthritis and pharmacological mechanisms: a focus on RANK/RANKL signaling. Biomed. Pharmacother., 2023, 167: 115646.

[98] Shangguan L, Ding M, Wang Y, Xu H, Liao B. Denosumab ameliorates osteoarthritis by protecting cartilage against degradation and modulating subchondral bone remodeling. Regen. Ther., 2024, 27: 181-190.

[99] Wittoek R, Verbruggen G, Vanhaverbeke T, Colman R, Elewaut D. RANKL blockade for erosive hand osteoarthritis: a randomized placebo-controlled phase 2a trial. Nat. Med., 2024, 30: 829-836.

[100] Amirkhizi F, Ghoreishy SM, Baker E, Hamedi-Shahraki S, Asghari S. The association of vitamin D status with oxidative stress biomarkers and matrix metalloproteinases in patients with knee osteoarthritis. Front. Nutrition, 2023, 10: 1101516.

[101] Busa P, Huang N, Kuthati Y, Wong C-S. Vitamin D reduces pain and cartilage destruction in knee osteoarthritis animals through inhibiting the matrix metalloprotease (MMPs) expression. Heliyon, 2023, 9: e15268.

[102] Srivastava RN, Srivastava SR, Raj S, Raj L. Effect of vitamin D intervention on knee osteoarthritis in vitamin D deficient subjects: a double blind, randomized, placebo controlled clinical trial. Osteoarthr. Cartil., 2024, 32: S299-S300.

[103] Sarig-Rapaport H, Krupnik S, Rowan TG. Amorphous calcium carbonate as a novel potential treatment for osteoarthritis in dogs: a pilot clinical study. Front. Veterinary Sci., 2024, 11: 1381941.

[104] Yang Y, et al.. Osteoarthritis treatment via the GLP-1–mediated gut-joint axis targets intestinal FXR signaling. Science, 2025, 388. ArticleID: eadt0548

[105] Mei J, Sun J, Wu J, Zheng X. Liraglutide suppresses TNF-alpha-induced degradation of extracellular matrix in human chondrocytes: a therapeutic implication in osteoarthritis. Am. J. Transl. Res., 2019, 11: 4800-4808

[106] Meurot C, et al.. Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. Sci. Rep., 2022, 12. ArticleID: 1567

[107] Bliddal H, et al.. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N. Engl. J. Med., 2024, 391: 1573-1583.

[108] Cheng J, Solomon T, Estee M, Cicuttini FM, Lim YZ. Effect of glucagon-like peptide-1 receptor agonists in osteoarthritis: a systematic review of pre-clinical and human studies. Osteoarthr. Cartil. Open, 2025, 7. ArticleID: 100567

[109] Halabitska I, Babinets L, Oksenych V, Kamyshnyi O. Diabetes and osteoarthritis: exploring the interactions and therapeutic implications of insulin, metformin, and GLP-1-based interventions. Biomedicines, 2024, 12: 1630.

[110] Wang X, et al.. Sustained therapeutic effects of self-assembled hyaluronic acid nanoparticles loaded with α-Ketoglutarate in various osteoarthritis stages. Biomaterials, 2024, 314. ArticleID: 122845

[111] Brochard S, et al.. A single intraarticular injection of a tranexamic acid-modified hyaluronic acid (HA/TXA) alleviates pain and reduces OA development in a murine model of monosodium iodoacetate-induced osteoarthritis. Front. Pharmacol., 2024, 15: 1456495.

[112] Rasmussen S, et al.. Intra-articular injection of gold micro-particles with hyaluronic acid for painful knee osteoarthritis. BMC Musculoskelet. Disord., 2024, 25. ArticleID: 211

[113] Tonutti A, et al.. The role of WNT and IL-1 signaling in osteoarthritis: therapeutic implications for platelet-rich plasma therapy. Front. Aging, 2023, 4. ArticleID: 1201019

[114] Patel S, et al.. Comparison of conventional dose versus superdose platelet-rich plasma for knee osteoarthritis: a prospective, triple-blind, randomized clinical trial. Orthop. J. Sports Med., 2024, 12. ArticleID: 23259671241227863

[115] Salman LA, Ahmed G, Dakin SG, Kendrick B, Price A. Osteoarthritis: a narrative review of molecular approaches to disease management. Arthritis Res. Ther., 2023, 25: 27.

[116] Ni HY, Zhang YP, Zhang XF. Therapeutic effect of San Bi Tang combined with glucosamine sulfate capsules in cold-dampness-type knee osteoarthritis. World J. Clin. Cases, 2024, 12: 3854-3865.

[117] Liu X, Dai H, Wang Z, Huang C, Huang K. Polyethylene glycol-stabilized cationic liposome encapsulating glucosamine sulfate: a promising nanoformulation for osteoarthritis therapy. AIP Adv, 2024, 14: 025137.

[118] Xu R, Zheng L, Huang M, Zhao M. High gastrointestinal digestive stability endows chondroitin sulfate-soluble undenatured type II collagen complex with high activity: improvement of osteoarthritis in rats. Int. J. Biol. Macromol., 2024, 257. ArticleID: 128630

[119] Chang Y-T, et al.. Evaluation of the protective effects of chondroitin sulfate oligosaccharide against osteoarthritis via inactivation of NLRP3 inflammasome by in vivo and in vitro studies. Int. Immunopharmacol., 2024, 142. ArticleID: 113148

[120] Sodhi H, Panitch A. A tunable glycosaminoglycan–peptide nanoparticle platform for the protection of therapeutic peptides. Pharmaceutics, 2024, 16: 173.

[121] Karateev AE, et al.. Outcomes of the use of the glycosaminoglycan-peptide complex as monotherapy and in combination with diacerein for the treatment of knee osteoarthritis in real-world practice. Cons. Med., 2023, 25: 105-112.

[122] Hu Q, Williams SL, Palladino A, Ecker M. Screening of MMP-13 inhibitors using a GelMA-alginate interpenetrating network hydrogel-based model mimicking cytokine-induced key features of osteoarthritis in vitro. Polymers, 2024, 16: 1572.

[123] Roy HS, et al.. On-demand release of a selective MMP-13 blocker from an enzyme-responsive injectable hydrogel protects cartilage from degenerative progression in osteoarthritis. J. Mater. Chem. B, 2024, 12: 5325-5338.

[124] Moqadami A, Khalaj-Kondori M, Hosseinpour Feizi MA, Baradaran B. Minocycline declines interleukin-1ß-induced apoptosis and matrix metalloproteinase expression in C28/I2 chondrocyte cells: an in vitro study on osteoarthritis. Excli J., 2024, 23: 114-129

[125] Hu Q, Ecker M. Overview of MMP-13 as a promising target for the treatment of osteoarthritis. Int. J. Mol. Sci., 2021, 22: 1742.

[126] Wojtowicz-Praga S, et al.. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J. Clin. Oncol., 1998, 16: 2150-2156.

[127] Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov., 2007, 6: 480-498.

[128] Grillet B, et al.. Matrix metalloproteinases in arthritis: towards precision medicine. Nat. Rev. Rheumatol., 2023, 19: 363-377.

[129] Ruminski PG, et al.. Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A highly selective and orally bioavailable matrix metalloproteinase-13 inhibitor for the potential treatment of osteoarthritis. J. Med. Chem., 2016, 59: 313-327.

[130] Allen KD, Thoma LM, Golightly YM. Epidemiology of osteoarthritis. Osteoarthr. Cartil., 2022, 30: 184-195.

[131] Troeberg L, Nagase H. Proteases involved in cartilage matrix degradation in osteoarthritis. Biochim. Biophys. Acta, 2012, 1824: 133-14.

[132] June RK, Liu-Bryan R, Long F, Griffin TM. Emerging role of metabolic signaling in synovial joint remodeling and osteoarthritis. J. Orthop. Res, 2016, 34: 2048-2058.

[133] Wang J, et al.. AMPK: implications in osteoarthritis and therapeutic targets. Am. J. Transl. Res, 2020, 12: 7670-7681

[134] Wang Y, Zhao X, Lotz M, Terkeltaub R, Liu-Bryan R. Mitochondrial biogenesis is impaired in osteoarthritis chondrocytes but reversible via peroxisome proliferator-activated receptor gamma coactivator 1alpha. Arthritis Rheumatol., 2015, 67: 2141-2153.

[135] Jin Z, et al.. Curcumin exerts chondroprotective effects against osteoarthritis by promoting AMPK/PINK1/Parkin-mediated mitophagy. Biomed. Pharmacother., 2022, 151. ArticleID: 113092

[136] Chen H, et al.. Ginsenoside Rh1 attenuates chondrocyte senescence and osteoarthritis via AMPK/PINK1/Parkin-mediated mitophagy. Int. Immunopharmacol., 2025, 159. ArticleID: 114911

[137] Li J, et al.. Metformin limits osteoarthritis development and progression through activation of AMPK signalling. Ann. Rheum. Dis., 2020, 79: 635-645.

[138] Tong X, et al.. Suppression of AMP-activated protein kinase reverses osteoprotegerin-induced inhibition of osteoclast differentiation by reducing autophagy. Cell Prolif., 2020, 53. ArticleID: e12714

[139] Pan F, et al.. Metformin for knee osteoarthritis in patients with overweight or obesity: a randomized clinical trial. JAMA, 2025, 333: 1804-1812.

[140] Minton DM, Elliehausen CJ, Javors MA, Santangelo KS, Konopka AR. Rapamycin-induced hyperglycemia is associated with exacerbated age-related osteoarthritis. Arthritis Res Ther., 2021, 23: 253.

[141] Zhang Y, Zhou Y. Advances in targeted therapies for age-related osteoarthritis: a comprehensive review of current research. Biomed. Pharmacother., 2024, 179: 117314.

[142] Khalil R, Diab-Assaf M, Lemaitre J-M. Emerging therapeutic approaches to target the dark side of senescent cells: new hopes to treat aging as a disease and to delay age-related pathologies. Cells, 2023, 12: 915.

[143] Escriche-Navarro B, Garrido E, Sancenón F, García-Fernández A, Martínez-Máñez R. A navitoclax-loaded nanodevice targeting matrix metalloproteinase-3 for the selective elimination of senescent cells. Acta Biomater., 2024, 176: 405-416.

[144] Wang X, Li X, Zhou J, Lei Z, Yang X. Fisetin suppresses chondrocyte senescence and attenuates osteoarthritis progression by targeting sirtuin 6. Chem.-Biol. Interact., 2024, 390. ArticleID: 110890

[145] Wang Y, et al.. Senomorphic agent pterostilbene ameliorates osteoarthritis through the PI3K/AKT/NF-κB axis: an in vitro and in vivo study. Am. J. Transl. Res., 2022, 14: 5243

[146] Dhanabalan KM, et al.. Intra-articular injection of rapamycin microparticles prevent senescence and effectively treat osteoarthritis. Bioeng. Transl. Med., 2023, 8: e10298.

[147] Luo Y, et al.. Inhibition of cc chemokine receptor 10 ameliorates osteoarthritis via inhibition of the phosphoinositide-3-kinase/Akt/mammalian target of rapamycin pathway. J. Orthop. Surg. Res., 2024, 19. ArticleID: 158

[148] Sahin K, et al.. Niacinamide and undenatured type II collagen modulates the inflammatory response in rats with monoiodoacetate-induced osteoarthritis. Sci. Rep., 2021, 11. ArticleID: 14724

[149] Volpi P, et al.. Effectiveness of a novel hydrolyzed collagen formulation in treating patients with symptomatic knee osteoarthritis: a multicentric retrospective clinical study. Int. Orthop., 2021, 45: 375-380.

[150] Mou D, et al.. Intra-articular injection of chitosan-based supramolecular hydrogel for osteoarthritis treatment. Tissue Eng. Regen. Med., 2021, 18: 113-125.

[151] Tarricone E, et al.. Anti-inflammatory performance of lactose-modified chitosan and hyaluronic acid mixtures in an in vitro macrophage-mediated inflammation osteoarthritis model. Cells, 2020, 9: 1328.

[152] Tsubosaka M, et al.. Gelatin hydrogels with eicosapentaenoic acid can prevent osteoarthritis progression in vivo in a mouse model. J. Orthop. Res., 2020, 38: 2157-2169.

[153] Rajagopal K, et al.. Long-term evaluation of allogenic chondrocyte-loaded PVA–PCL IPN scaffolds for articular cartilage repair in rabbits. Indian J. Orthop., 2021, 55: 853-860.

[154] Zerrillo L, et al.. PLGA nanoparticles grafted with hyaluronic acid to improve site-specificity and drug dose delivery in osteoarthritis nanotherapy. Nanomaterials, 2022, 12: 2248.

[155] Ma J-C, et al.. Exploring the translational potential of PLGA nanoparticles for intra-articular rapamycin delivery in osteoarthritis therapy. J. Nanobiotechnol., 2023, 21. ArticleID: 361

[156] Lee C-Y, et al.. Development and functional evaluation of a hyaluronic acid coated nano-formulation with kaempferol as a novel intra-articular agent for Knee Osteoarthritis treatment. Biomed. Pharmacother., 2024, 175. ArticleID: 116717

[157] Wei L, Pan Q, Teng J, Zhang H, Qin N. Intra-articular administration of PLGA resveratrol sustained-release nanoparticles attenuates the development of rat osteoarthritis. Mater. Today Biol., 2024, 24. ArticleID: 100884

[158] Gandhi S, Shende P. Anti-CD64 antibody-conjugated PLGA nanoparticles containing methotrexate and gold for theranostics application in rheumatoid arthritis. AAPS PharmSciTech, 2024, 25: 22.

[159] Ain QU, et al.. QbD-based fabrication of biomimetic hydroxyapatite embedded gelatin nanoparticles for localized drug delivery against deteriorated arthritic joint architecture. Macromol. Biosci., 2024, 24. ArticleID: 2300336

[160] Esmaeili A, et al.. Co-aggregation of MSC/chondrocyte in a dynamic 3D culture elevates the therapeutic effect of secreted extracellular vesicles on osteoarthritis in a rat model. Sci. Rep., 2022, 12. ArticleID: 19827

[161] Yan J, et al.. Autophagic LC3⁺ calcified extracellular vesicles initiate cartilage calcification in osteoarthritis. Sci. Adv., 2022, 8. ArticleID: eabn1556

[162] Feng K, et al.. Reversing the surface charge of MSC-derived small extracellular vesicles by εPL-PEG-DSPE for enhanced osteoarthritis treatment. J. Extracell. Vesicles, 2021, 10. ArticleID: e12160

[163] He L, et al.. Bone marrow mesenchymal stem cell-derived exosomes protect cartilage damage and relieve knee osteoarthritis pain in a rat model of osteoarthritis. Stem Cell Res. Ther., 2020, 11: 276.

[164] Jiang Z, Wang H, Zhang Z, Pan J, Yuan H. Cartilage targeting therapy with reactive oxygen species-responsive nanocarrier for osteoarthritis. J. Nanobiotechnol., 2022, 20. ArticleID: 419

[165] Zhou T, et al.. Hypoxia and matrix metalloproteinase 13-responsive hydrogel microspheres alleviate osteoarthritis progression in vivo. Small, 2024, 20. ArticleID: 2308599

[166] Xiong F, et al.. pH-responsive and hyaluronic acid-functionalized metal–organic frameworks for therapy of osteoarthritis. J. Nanobiotechnol., 2020, 18. ArticleID: 139

[167] Porcello A, et al.. Thermo-Responsive Hyaluronan-Based Hydrogels Combined with Allogeneic Cytotherapeutics for the Treatment of Osteoarthritis. Pharmaceutics, 2023, 15: 1528.

[168] Abdelhamid MM, et al.. The Evaluation of cartilage regeneration efficacy of three-dimensionally biofabricated human-derived biomaterials on knee osteoarthritis: a single-arm, open label study in Egypt. J. Personal. Med., 2023, 13: 748.

[169] Liu Y, et al.. 3D-bioprinted BMSC-laden biomimetic multiphasic scaffolds for efficient repair of osteochondral defects in an osteoarthritic rat model. Biomaterials, 2021, 279. ArticleID: 121216

Funding

National Natural Science Foundation of China (National Science Foundation of China)(82394445, 82161160342, 82030067, 82172397)

National Key Research and Development Program of China-2022YFA1207500

RIGHTS & PERMISSIONS

The Author(s)